What are the adverse reactions of Riboxil/Calilon?

Ribociclib is a CDK4/6 inhibitor commonly used to treat HR-positive, HER2-negative advanced breast cancer, usually in combination with tamoxifen or aromatase inhibitors. As a targeted drug, Riboxiclib prevents the proliferation and growth of cancer cells by inhibiting the activity of CDK4 and CDK6 kinases in the cell cycle. However, although it can effectively control tumor growth, it may also cause some adverse reactions during treatment.

1. Hematological abnormalities: A significant side effect of Riboxil is leukopenia, especially neutropenia. Patients need to have regular blood tests monitored during treatment, as a decrease in white blood cell counts may make patients more susceptible to infection. Some patients may develop thrombocytopenia or anemia, which may lead to bleeding or increased fatigue.

2. Liver function damage: Riboxiclib may affect the liver and lead to abnormal liver function. Patients usually need regular liver function tests during treatment. If liver function indicators are abnormal, dose adjustment or treatment suspension may be necessary.

3. QT interval prolongation: Riboxiclib may cause QT interval prolongation, which requires special attention. Prolonged QT interval may cause cardiac arrhythmias, especially in patients with underlying heart problems. If palpitations or other symptoms of cardiac discomfort occur during treatment, patients should report to their doctor in time.

4. Fatigue and weakness: The use of Riboxil may also be accompanied by symptoms such as fatigue, weakness, and loss of appetite. These side effects may affect patients' daily life and work, but can usually be alleviated by adjusting drug dosage or taking symptomatic treatment.

Although Riboxil may cause some side effects, with proper monitoring and management under the guidance of a doctor, these adverse reactions can be effectively controlled. Patients should undergo regular blood, liver function and electrocardiogram tests while taking reboxil to ensure the safety of the treatment.

Reference materials:https://us.kisqali.com/